The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Discovering New Biomarkers In Hepatocellular Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Liver cancer is a leading cause of cancer death with increasing rates and a high mortality. The project will develop new methods to predict liver cancer risk and outcomes using circulating samples rather than invasive biopsies. Our data shows that tissue and cells shed specific blebs into the circulation and these can contain unique information about the tissue of origin. We propose a series of experiments to show that these circulating samples are able to predict risk and outcomes with liver
Loop-mediated Isothermal Amplification(LAMP): A Novel Tool For The Diagnosis Of Mixed Malaria Infections In Elimination Settings
Funder
National Health and Medical Research Council
Funding Amount
$101,877.00
Summary
The malaria elimination agenda will require the development of novel, field applicable diagnostic tools to detect asymptomatic carriers of P.falciparum and non-falciparum malaria infections. Loop-mediated isothermal amplification (LAMP) has been demonstrated to be a novel, sensitive, specific nucleic acid amplification technique. My project aims to optimise LAMP into a high-throughput field applicable molecular diagnostic tool capable of diagnosing malaria in elimination settings
Big Data To Inform The Impact Of Antibiotics And Proton Pump Inhibitors On Immunotherapies Used To Treat Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$115,883.00
Summary
Antibiotics and proton pump inhibitors (PPIs) affect gut bacteria health. Gut bacteria are involved in the function of the immune system and potentially the effectiveness of immunotherapies. However, the impact of antibiotics and PPIs on the efficacy of immunotherapies is unknown. Newly available big data will be used to determine the impacts of antibiotics and PPIs on immunotherapy efficacy, informing on the best cancer treatments to use in patients who require antibiotics or PPIs.
This project aims to comprehensively evaluate the role of androgen receptor (AR) signalling in breast cancer by identifying changes in AR signalling and its role in an endocrine resistant setting. Understanding the changes in AR signalling in either treatment-naive or treatment-resistant context would better assist in the identification for opportunities to modulate AR signalling as a therapeutic target in breast cancer.
Indwelling Pleural Catheter For Management Of Cancer-related Pleural Effusions
Funder
National Health and Medical Research Council
Funding Amount
$123,688.00
Summary
Most cancers can be complicated by fluid accumulation (effusion) in the (pleural) cavity between the lung and chest wall, causing significant breathlessness. Indwelling pleural catheter (IPC) is a new method that allows patients to drain the effusion outside the hospital and avoid further invasive interventions. This study aims to provide important information that will help guide use of IPC and manage its complications, especially infection, improve patient outcomes and save healthcare costs.
Understanding The Clinical Significance Of Tumour Genomic Architecture And Host Immune Response In Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$94,732.00
Summary
This study uses sophisticated DNA sequencing technologies to help patients and their doctors better understand and treat breast cancer. It also tries to understand how the cancer DNA may change over time, and if this is important to how the cancer is treated. In addition, it looks for a link between the DNA changes in a tumour and the anti-tumour immune response, which may help identify patients that could benefit from immunotherapy in the future.
CLINICAL CHARACTERIZATION OF GENETICALLY DEFINED GERMLINE SUB-GROUPS OF MELANOMA AND BREAST CANCER PATIENTS.
Funder
National Health and Medical Research Council
Funding Amount
$140,949.00
Summary
In this project I will assess how cancer patients’ genetic makeup influences the nature and outcome of their cancer, especially in terms of how successful treatment is likely to be. We will show how key genetic variants influence cancer behaviour and by combining these genes we will have a better understanding of how to develop more successful treatments.
Assessment Of The Effects Of Pathogenic Germline TP53 Mutations; International Sarcoma Kindred Study Participants’ Views Of Feedback Of Genetic Research Results And The Acceptability Of Taking Part In A Pilot Screening Programme
Funder
National Health and Medical Research Council
Funding Amount
$55,242.00
Summary
The International Sarcoma Kindred Study (ISKS) aims to identify individuals who harbour germline TP53 mutations. TP53 mutations are characterised by the development of multiple cancers including sarcoma. This project will assess ISKS participants’ views of the feedback of genetic research information and will develop sensitive feedback practices. The acceptability and psychological impact of taking part in a pilot screening protocol designed for cancer-prone populations will also be assessed.
Lung cancer is a leading cause of cancer death globally. Symptoms may not develop until disease is advanced, so it is often incurable at diagnosis. Scientific developments have greatly improved our ability to test for the changes in DNA structure and function responsible for this deadly disease and its progression. This study examines whole lung cancer genomes then uses these findings to develop safer methods for detection based on changes in DNA sequence.